



May 3, 2023

**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001  
Scrip code: 532531

**The National Stock Exchange of India Limited**  
Exchange Plaza, Bandra-Kurla Complex  
Bandra (E) Mumbai - 400 051  
Scrip code: STAR

Dear Madam/ Sir,

**Sub: Press Release**

Please find attached Press Release issued by the Company titled:

**“Strides and Orbicular enter into a strategic partnership to  
jointly develop a range of nasal sprays”**

Thanks & Regards,  
For **Strides Pharma Science Limited**,

**Manjula Ramamurthy**  
**Company Secretary**

Encl. As above

**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India | Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

corpcomm@strides.com, www.strides.com

## Strides and Orbicular enter into a strategic partnership to jointly develop a range of nasal sprays

- *Partnership to leverage Orbicular's advanced development capabilities with Strides' USFDA approved manufacturing site for Nasal Sprays at Chestnut Ridge, New York*
- *Strides to launch these products Globally through its commercial arms across the regions*

**Bangalore and Hyderabad, India, May 03, 2023** - Strides Pharma Science Ltd (BSE: 532531, NSE: STAR, Strides or Company) and Orbicular Pharmaceutical Technologies Private Limited (Orbicular) today informed that they have entered into a strategic partnership to develop, manufacture and commercialize nasal sprays for the global markets.

Orbicular, a speciality pharmaceutical company focused on research and product development, will use its expertise in drug delivery and formulation to develop nasal sprays for global markets. The Company has deployed a thorough product design approach to ensure the nasal sprays are robust, following "Quality-by-Design" principles. Orbicular has a stellar product development and licensing track record across various Complex Injectables, Topicals, Ophthalmic, Parenteral, Nasal Spray, and Inhalation product assets.

Strides will commercialize these nasal sprays across the markets using its commercial engine in the US, Europe, and several other markets. The products will be manufactured at Company's state-of-the-art Chestnut Ridge, New York facility. The facility has comprehensive capabilities for nasal spray manufacturing in the unit dose and multi-dose format, including for controlled substances. The site has been in continuous operation for four decades with approval from USFDA and Drug Enforcement Administration (DEA) with a strong compliance track record. Strides acquired this facility in October 2021 from Endo Inc.

The partnership will commercialize four nasal sprays with a combined Global IQVIA market size in excess of \$400m.

### About Strides

Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy and an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on "difficult to manufacture" products sold in over 100 countries. Additional information is available at the Company's website at [www.strides.com](http://www.strides.com).

### About Orbicular

Orbicular Pharmaceutical Technologies Private Limited (Orbicular) is a research-oriented pharmaceutical product development company with proven capabilities across various dosage forms. The Company's business strategy revolves around developing niche generic and specialty pharmaceutical products and licensing them to global partners at late stages. The company's ambitious strategic plan is to execute the defined CI-TOP SPIN (Complex Injectables, Topicals, Ophthalmic, Parenteral, Nasal Sprays, and Inhalations) Strategy for both Regulated and Emerging Markets. The Company intelligently selects products and proactively executes regulatory expectations. For details, please visit <https://orbicular.co.in/>

**For further information, please contact:**

## Strides

### **Badree Komandur**

Executive Director – Finance & Group CFO

+91 80 6784 0747

### **Ankit Gupta**

Vice President- Corporate Strategy and Development

+91 80 6784 0145

Email: [ankit.gupta@strides.com](mailto:ankit.gupta@strides.com)

## Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Regd. Office: 201, 'Devavrata', Sector - 17, Vashi, Navi  
Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta Road,  
Bengaluru – 560076

## Corporate Communication

**Pallavi Panchmatia:** +91 80 6784 0193

Email: [pallavi.panchmatia@strides.com](mailto:pallavi.panchmatia@strides.com)

## PR Consultancy

Fortuna PR

K Srinivas Reddy: +91 90005 27213

[srinivas@fortunapr.com](mailto:srinivas@fortunapr.com)

Boni Mukherjee: +91 96186 82208

[boni@fortunapr.com](mailto:boni@fortunapr.com)